P-beta Protein: A Potential Drug Target for Neurological Disorders

Target Name: PARL

NCBI ID: G55486

PARL

P-beta Protein: A Potential Drug Target for Neurological Disorders

PARL (P-beta), also known asBecapimab, is a protein that is expressed in various tissues throughout the body, including the brain, and plays a crucial role in the development and maintenance of normal brain function. It is a small protein that belongs to the beta-amyloid protein (BAPP) family, which is known for its role in the development of Alzheimer's disease.

The P-beta protein is made up of 116 amino acid residues and has a calculated molecular weight of 11.9 kDa. It is highly conserved, with only one amino acid residue being significantly different from its human counterpart. This consistency is important for its function, as the P-beta protein is able to interact with several other proteins with high degree of identity.

One of the key functions of the P-beta protein is its role in the regulation of normal brain function. It is involved in the formation and maintenance of the blood-brain barrier, which is a specialized barrier that separates the brain from the surrounding bloodstream. This barrier is essential for the survival of the brain and allows it to function independently.

In addition to its role in the formation and maintenance of the blood-brain barrier, the P-beta protein is also involved in the regulation of several other processes that are important for brain health. For example, it is involved in the development and maintenance of synaptic plasticity, which is the ability of the brain to change and adapt in response to new experiences. It is also involved in the regulation of neurotransmitter release, which is important for the proper functioning of the brain.

The P-beta protein is also of interest as a potential drug target. Its role in the regulation of normal brain function makes it an attractive target for the development of new treatments for a variety of neurological disorders, including Alzheimer's disease. In addition, its small size and high degree of conservation make it an attractive candidate for small molecule inhibitors.

Research has also shown that the P-beta protein is involved in several other cellular processes that are important for brain health. For example, it is involved in the regulation of cell survival, and has been shown to play a role in the development of neurofibrillary tangles, which are a hallmark of Alzheimer's disease. It is also involved in the regulation of cell signaling, and has been shown to play a role in the development of neuroendocrine dysfunction.

In conclusion, the P-beta protein is a protein that is expressed in various tissues throughout the body and plays a crucial role in the development and maintenance of normal brain function. Its role in the regulation of normal brain function makes it an attractive target for the development of new treatments for a variety of neurological disorders, including Alzheimer's disease. Its small size and high degree of conservation make it an attractive candidate for small molecule inhibitors, and its involvement in several other cellular processes that are important for brain health makes it a promising candidate for further research.

Protein Name: Presenilin Associated Rhomboid Like

Functions: Required for the control of apoptosis during postnatal growth. Essential for proteolytic processing of an antiapoptotic form of OPA1 which prevents the release of mitochondrial cytochrome c in response to intrinsic apoptotic signals (By similarity). Required for the maturation of PINK1 into its 52kDa mature form after its cleavage by mitochondrial-processing peptidase (MPP) (PubMed:22354088). Promotes changes in mitochondria morphology regulated by phosphorylation of P-beta domain (PubMed:14732705, PubMed:17116872). Required for processing of CLPB into a form with higher protein disaggregase activity by removing an autoinhibitory N-terminal peptide (PubMed:32573439)

The "PARL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PARL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets